

Nessan Bermingham, PhD
Founder & Managing Partner, Bio Equity

Nessan Bermingham is co-founder and a managing partner of Bio Equity. Prior to forming Bio Equity, Nessan was a partner at Omega Funds, a direct secondary healthcare fund that makes investments in the U.S. and Europe. Nessan opened Omega's Boston office, and led the firm's expansion into the U.S. healthcare market. While at Omega, he successfully completed multiple portfolio acquisitions, was a board member for Precisense (www.precisense.dk) and NsGene (www.nsgene.dk), and was a board observer and advisor for multiple companies.

Prior to joining Omega Funds, Nessan was a partner at Atlas Venture, where he focused on the U.S. public markets and EU private biotech markets. While at Atlas he was a board member for Renovo (www.renovo.com), Arrow Therapeutics (acquired by AstraZeneca) and Cellzome (www.cellzome.com). Nessan was also a co-founder of Serentis (www.serentis-pharma.com), a UK-based biotech company. Prior to joining Atlas Venture, Nessan was a biopharma research analyst at UBS Warburg.

Nessan was a Howard Hughes Associate Fellow at Baylor College of Medicine, earned a Ph.D. in molecular biology from Imperial College London, and a B.S from Queen's University in Belfast, Northern Ireland. He has been published in several science and healthcare journals, including Science, Neuron and Development. Nessan is also a mentor in the Boston University Health Care Entrepreneurship Program. He resides in Boston, and is married with three children.

Bio Equity is a healthcare-focused special situations investment firm located in Boston, Massachusetts. Our investment approach provides solutions for general partners, limited partners and corporations through our expertise in direct secondary investing, annex fund investing and portfolio management.